Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study

Yi-Hsuan Hsieh1,2 | Hsiang-Lin Chan2,3 | Chiao-Fan Lin2,3 | Sophie Hsin-Yi Liang1,2 | Mong-Liang Lu4 | Roger S. McIntyre5,6 | Yena Lee5 | Tzu-Chin Lin7 | Wei-Che Chiu8,9 | Vincent Chin-Hung Chen2,10

1Department of Child Psychiatry, Chang Gung Memorial Hospital at Taoyuan, Taoyuan, Taiwan
2Department of Medicine, Chang Gung University, Taoyuan, Taiwan
3Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
4Department of Psychiatry, Wan-Fang Hospital & School of Medicine, Taipei Medical University, Taipei, Taiwan
5Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, Toronto, ON, Canada
6Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7Bethel Psychiatric Clinic, Taipei, Taiwan
8Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan
9School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
10Department of Psychiatry, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

Abstract
Objective: The association between antipsychotic use and gastric cancer risk remains unclear. Therefore, this study aimed to determine the association between antipsychotic exposure and the incidence of gastric cancer.

Methods: Using a nested case-control design, a total of 34,470 gastric cancer patients and 163,430 nongastric cancer controls were identified from Taiwan's National Health Insurance Research Database between 1 January 1997 and 31 December 2013. We analyzed the data using a conditional logistic regression model to adjust for possible confounding variables.

Results: Antipsychotic use was independently inversely associated with gastric cancer risk after controlling for potential confounding factors including income, urbanization, medications, physical and medical illness, aspirin use, nonsteroidal anti-inflammatory drug use and triple therapy. In addition, dose-dependent trends against gastric cancer risk were also shown with individual antipsychotic compounds including thioridazine, haloperidol, sulpiride, clozapine, olanzapine, quetiapine, amisulpride, and risperidone. A sensitivity analysis showed that second-generation...
1 | BACKGROUND

Gastric cancer results in 738,000 deaths worldwide every year, and it is the third and fifth leading cause of cancer death among men and women, respectively. As its early features are often subclinical, the clinical presentation of gastric cancer often indicates a more advanced stage of illness frequently associated with metastasis. Consequently, poor 5-year survival rates of less than 40% have been reported in the literature. Due to its limited treatment response, the development of novel and safe therapeutic agents is warranted.

The etiology and pathogenesis of gastric cancer are not known but are generally thought to be multifactorial. One of the several factors associated with gastric cancer is alterations in monoaminergic signaling. Results focusing on the dopamine system and gastric cancer have been inconsistent. Chakroborty et al. mentioned that dopamine treatment can retard the growth of gastric cancer by inhibiting angiogenesis; Gangury et al. described dopamine’s effects in inhibiting gastric cancer cell proliferation; Huang et al. found that dopamine could suppress gastric cancer cell invasion and migration. However, some studies supported the antitumor effects of dopamine antagonists in gastric cancer: Mu et al. discovered that thioridazine induced gastric cancer cell apoptosis, and thioridazine pretreatment inhibited the growth of NCI-N87 cell-derived tumors in vivo. In addition, one recent study showed that the expression of dopamine receptor D2 (DRD2) was negatively correlated with survival durations in patients with gastric cancer, and thus DRD2 antagonists were considered a possible efficient choice in gastric cancer therapy.

Antipsychotics had significant dose-dependent effects in reducing the risk of gastric cancer risk in patients with and without peptic ulcer disease.

Conclusions: Antipsychotic use was inversely associated with gastric cancer risk, and dose-dependent effects against gastric cancer were also seen with several individual antipsychotic compounds.

Keywords: cancer risk factors, clinical cancer research, digestive cancer

2 | METHODS

2.1 | Nationwide population-based study

The Taiwan National Health Insurance program, which has been in operation since 1995, covers approximately 99% of Taiwan’s population. The population in this study was retrieved from the NHIRD between 1 January 1997 and 31 December 2013. We collected information on personal data, diagnostic codes, medical procedures, and medication prescriptions. Cases of gastric cancer were identified within the NHIRD using the International Classification of Diseases, Ninth Revision (ICD-9) code of 151. All included cases had at least two outpatient or one inpatient diagnosis of gastric cancer. We confirmed the diagnosis by linkage to the Catastrophic Illness Registry Dataset. The date of the first gastric cancer claim was defined as the index date.

Five non-gastric cancer controls before the index date were randomly selected for each case of gastric cancer using incidence density sampling. The controls and gastric cancer cases were matched by sex and year of birth. We excluded individuals who had discontinued health insurance or died before the index date of the matched cases (n = 8920) (Figure 1).

2.2 | Exposure assessment

Data on antipsychotics prescriptions were obtained from the NHIRD. Antipsychotics were classified into FGAs and SGAs. FGAs included chlorpromazine, levomepromazine, fluphenazine, perphenazine, prochlorperazine,
triluoperazine, thioridazine, haloperidol, flupentixol, clo-
penthixol, chlorprothixene, zuclopenthixol, pimozide, 
loxapine, and sulpiride. SGAs included ziprasidone, clozap-
ine, olanzapine, quetiapine, amisulpride, risperidone, zote-
pine, aripiprazole, and paliperidone. A list of the Anatomical 
Therapeutic Chemical codes is provided in the Appendix 
1. We used the defined daily dose (DDD) by the World 
Health Organization to measure antipsychotic exposure,17 
and graded the cumulative defined daily dose(cDDD) as 
follows: 0–27 DDD; 28–83 DDD; 84–167 DDD; and equal 
to or great than 168 DDD (≥168 DDD). The cDDD was 
estimated to present the total sum of a dispensed DDD, and 
related to the exposure duration of antipsychotics. To inves-
tigate whether antipsychotic use was an independent risk 
factor for gastric cancer, antipsychotic use over the previous 
year was excluded to diminish protopathic bias. 

Potentially confounding factors were assessed, includ-
ing concomitant medication use and comorbid medical 
disorders. Concomitant medication use included aspirin, 
nonsteroidal anti-inflammatory drugs (NSAIDs), statins, 
and triple therapy (combination of proton pump inhibitors, 
amoxicillin, and clarithromycin for H. pylori infection). 
Hypertension, hyperlipidemia, diabetes, chronic obstruc-
tive pulmonary disease (COPD), chronic kidney disease, 
peptic ulcer, liver cirrhosis, psychotic disorder, depressive 
disorder, and anxiety disorder were defined as comorbid 
medical disorders. One previous study found patients with 
schizophrenia had lower incidence of gastric cancer during 
9-year follow-up period,18 so we included psychotic disor-
der as an important confounding factor and then adjusted 
it. Previous studies have reported that heavy alcohol drink-
ing and smoking are risk factors for gastric cancer,11,19,20
| Characteristics         | Gastric cancer, n = 34470 (%) | Nongastric cancer, n = 163430 (%) | P value |
|-------------------------|--------------------------------|----------------------------------|---------|
| Gender                  |                                |                                  |         |
| Female                  | 15368 (44.58)                  | 73558 (45.01)                    | 0.15    |
| Male                    | 19102 (55.42)                  | 89872 (54.99)                    |         |
| Age at index date, year |                                |                                  |         |
| 18-45                   | 8456 (24.53)                   | 40756 (24.94)                    | 0.0002  |
| 45-60                   | 12273 (35.60)                  | 59488 (36.40)                    |         |
| ≥60                     | 13741 (39.86)                  | 63186 (38.66)                    |         |
| Urbanizationa           |                                |                                  |         |
| Low                     | 2660 (7.72)                    | 13633 (8.34)                     | <0.0001 |
| Moderate                | 5671 (16.45)                   | 28090 (17.19)                    |         |
| High                    | 15955 (46.29)                  | 74490 (45.58)                    |         |
| Very high               | 10184 (29.54)                  | 47217 (28.89)                    |         |
| Income (NTDb)           |                                |                                  |         |
| 0                       | 6296 (18.27)                   | 28479 (17.43)                    | <0.0001 |
| 1-25000                 | 5362 (15.56)                   | 25327 (15.50)                    |         |
| 25001-40000             | 16012 (46.45)                  | 73875 (45.20)                    |         |
| ≥40001                  | 6800 (19.73)                   | 35749 (21.87)                    |         |
| Aspirin, (cDDD >28)c    | 7089 (20.57)                   | 32990 (20.19)                    | 0.11    |
| NSAIDs, (cDDD >28)c     | 22260 (64.58)                  | 108011 (66.09)                   | <0.0001 |
| Statins, (cDDD >28)c    | 3748 (10.87)                   | 17696 (10.83)                    | 0.81    |
| Triple therapy          | 1824 (5.29)                    | 7421 (4.54)                      | <0.0001 |
| Antipsychotics, cDDDc   |                                |                                  |         |
| 0-27                    | 33957 (98.51)                  | 159618 (97.67)                   | <0.0001 |
| 28-83                   | 360 (1.04)                     | 1958 (1.20)                      |         |
| 84-167                  | 73 (0.21)                      | 613 (0.38)                       |         |
| ≥168                    | 80 (0.23)                      | 1241 (0.76)                      |         |
| Medical diseases        |                                |                                  |         |
| Hypertension            | 11740 (34.06)                  | 53577 (32.78)                    | <0.0001 |
| Hyperlipidemia          | 5596 (16.23)                   | 26885 (16.45)                    | 0.33    |
| Diabetes                | 6108 (17.72)                   | 24633 (15.07)                    | <0.0001 |
| COPD                    | 5664 (16.43)                   | 25195 (15.42)                    | <0.0001 |
| Chronic kidney disease  | 883 (2.56)                     | 2676 (1.64)                      | <0.0001 |
| Peptic ulcer            | 9423 (27.34)                   | 35988 (22.02)                    | <0.0001 |
| Cirrhosis               | 4468 (12.96)                   | 18535 (11.34)                    | <0.0001 |
| Psychotic disorder      | 217 (0.63)                     | 2129 (1.30)                      | <0.0001 |
| Depressive disorder     | 1244 (3.61)                    | 7215 (4.41)                      | <0.0001 |
| Anxiety disorder        | 5487 (15.92)                   | 27768 (16.99)                    | <0.0001 |
| Alcohol-related disease | 241 (0.70)                     | 648 (0.40)                       | <0.0001 |

Abbreviation: cDDD, cumulative defined daily dose; COPD: chronic obstructive pulmonary disease; NSAIDs, nonsteroidal anti-inflammatory drugs.

*aQuartiles by human development index.

b1 US $ = 32.1 New Taiwan Dollars (NTD) in 2008.

cDrug dose usage is the cDDD excluding the year before the index date.
but alcohol drinking and smoking are not recorded in the NHIRD. Therefore, we examined alcohol-related disease instead of alcohol drinking, and assessed COPD as a proxy for smoking status.

2.3 | Statistical methods

We reported descriptive statistics for personal characteristics, medical use, and comorbid illness of gastric cancer cases and controls. We carried out conditional logistic regression models using SAS Version 9.4 (SAS Institute, Cary, NC). To investigate the impact of antipsychotics on gastric cancer risk, the cumulative exposure was divided into four subgroups by DDDs, as mentioned above. We adjusted the personal data and confounding factors, and calculated the crude odds ratio (OR) and the adjusted OR. A \( P < 0.05 \) indicated statistical significance.

We also divided antipsychotics into FGAs and SGAs, and selected nine common antipsychotics (ie, thioridazine, haloperidol, sulpiride, clozapine, olanzapine, quetiapine, amisulpride, risperidone, and aripiprazole) for further individual assessment. We also adopted sensitivity analysis for peptic ulcer disease to minimize possible bias.

2.4 | Ethics statement

The study was approved by the Institutional Review Board of Chang Gung Medical Foundation (No. 201700253B0C501).

3 | RESULTS

3.1 | Sample characteristics

We summarized the personal and clinical characteristics in Table 1. A total of 34,470 gastric cancer patients and 163,430 nongastric cancer controls were included between 1 January 1997 and 31 December 2013. The levels of urbanization

| Variables                          | Unadjusted analysis | Adjusted analysisa |
|------------------------------------|---------------------|--------------------|
|                                   | Odds ratio (95% CI) | P value            |
|                                    |                     | Odds ratio (95% CI) | P value |
| **Antipsychotics, cDDD**          |                     |                    |
| 0-27                               | 1.00 [reference]    | 1.00 [reference]   |
| 28-83                              | 0.83 (0.74-0.93)    | 0.0013             | 0.82 (0.73-0.92) | 0.0005 |
| 84-167                             | 0.53 (0.41-0.68)    | <0.0001            | 0.55 (0.43-0.70) | <0.0001 |
| ≥168                               | 0.29 (0.23-0.36)    | <0.0001            | 0.35 (0.27-0.45) | <0.0001 |
| **Aspirin (cDDD >28)**            | 0.96 (0.93-0.99)    | 0.007              | 0.94 (0.91-0.98) | 0.0009 |
| **NSAIDs (cDDD >28)**             | 0.87 (0.84-0.89)    | <0.0001            | 0.85 (0.82-0.87) | <0.0001 |
| **Triple therapy, yes vs no**     | 1.14 (1.08-1.20)    | <0.0001            | 0.96 (0.91-1.01) | 0.14    |
| **Medical diseases, yes vs no**   |                     |                    |
| Hypertension                       | 1.00 (0.98-1.03)    | 0.81               | 1.00 (0.97-1.04) | 0.83    |
| Diabetes                           | 1.19 (1.15-1.23)    | <0.0001            | 1.22 (1.18-1.26) | <0.0001 |
| Hyperlipidemia                     | 0.94 (0.90-0.97)    | <0.0001            | 0.88 (0.84-0.91) | <0.0001 |
| Chronic kidney disease             | 1.49 (1.38-1.61)    | <0.0001            | 1.41 (1.31-1.53) | <0.0001 |
| Peptic ulcer                       | 1.31 (1.27-1.35)    | <0.0001            | 1.38 (1.34-1.42) | <0.0001 |
| Alcohol-related liver disease      | 1.74 (1.50-2.02)    | <0.0001            | 1.73 (1.49-2.01) | <0.0001 |
| Psychotic disorder                 | 0.47 (0.41-0.54)    | <0.0001            | 0.45 (0.39-0.52) | <0.0001 |
| Anxiety disorder                   | 0.88 (0.85-0.91)    | <0.0001            | 0.87 (0.84-0.90) | <0.0001 |

Abbreviations: cDDD, cumulative defined daily dose; CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs.

aAdjusted for sex, age, income, urbanization, hypertension, diabetes, hypercholesterolemia, chronic kidney disease, depressive disorder, peptic ulcer, alcohol-related liver disease, psychotic disorder, anxiety disorder, aspirin, NSAIDs, and triple therapy.

bDrug dose usage is the cDDD excluding the year before the index date.
had significant differences in these two groups \( (P < 0.001) \). Higher incidence rates of hypertension, diabetes, COPD, chronic kidney disease, peptic ulcer, liver cirrhosis, and alcohol-related disease, as well as lower incidence rates of psychotic disorder, depressive disorder, and anxiety disorder were found in the gastric cancer group compared with the control group. Gastric cancer patients received fewer NSAIDs, fewer total antipsychotics and more triple therapy than controls.

### 3.2 Association between antipsychotic use and gastric cancer risk

We conducted multivariate analysis, and revealed the association between antipsychotic use and gastric cancer risk in Table 2. Antipsychotic use was independently inversely associated with gastric cancer risk after controlling for potential confounding factors including income, urbanization, medication, psychiatric and medical illness, aspirin use, NSAID use, and triple therapy. A trend of a dose-dependent relationship was also noted in the adjusted analysis; when the cumulative DDD (cDDD) of antipsychotics increased, the odds ratio of gastric cancer decreased. The OR was 0.35 (95% CI = 0.27-0.45) in those with cDDDs \( \geq 168 \).

The adjusted results also revealed that diabetes, chronic kidney disease, peptic ulcer, and alcohol-related disease were associated with a higher gastric cancer risk, while aspirin use, NSAID use, hyperlipidemia, anxiety disorder, and psychotic disorder were negatively associated with gastric cancer risk.

In Table 2, triple therapy is associated with gastric cancer risk before conducting adjusted analysis. Indication bias should be considered: triple therapy is indicated for H. pylori infection which is a confirmed risk factor for gastric cancer.\(^{10-12}\) After conducting adjusted analysis, there was a decrease in gastric cancer risk associated with triple therapy. Results from recent studies have identified that H. pylori eradication was associated with decreased gastric cancer risk;\(^{21-23}\) thus we controlled triple therapy and peptic ulcer diseases as impairment confounding factors in the further analysis.

### 3.3 Individual antipsychotics

The association between individual antipsychotics and gastric cancer risk is shown in Table 3. The exact duration of antipsychotics use was provided in the Appendix 2. The negative association with gastric cancer risk remained when FGAs and SGAs were examined separately: the ORs for cDDD \( \geq 168 \) were 0.39 (95% CI = 0.31-0.50) and 0.21 (95% CI = 0.13-0.33), respectively. Three FGAs (ie, thioridazine, haloperidol, and sulpiride) and six common SGAs (ie, clozapine, olanzapine, quetiapine, amisulpride, risperidone, and aripiprazole) were analyzed, and all antipsychotic compounds showed negative associations with gastric cancer risk except aripiprazole. Besides, dose-dependent protective trends were considered.

### 3.4 Sensitivity analysis

To minimize bias from peptic ulcer disease as a major cofounding factor, we analyzed gastric cancer patients in subgroups of those with and without gastric ulcer disease (Table 4). In these two subgroups, antipsychotics including FGAs and SGAs both showed negative associations with gastric cancer risk, and dose effects were obviously observed. With cDDDs \( \geq 168 \), SGAs significantly decreased the risk of gastric cancer; the OR was 0.21 (95% CI = 0.10-0.45) in patients with a gastric ulcer history, and 0.19 (95% CI = 0.10-0.38) in those without a gastric ulcer history.

### 4 DISCUSSION

To our knowledge, this is the first study assessing the association between antipsychotics and gastric cancer risk using a population-based design; we found that the incidence of gastric cancer was inversely associated with antipsychotic use after controlling for potential confounding factors. Our findings agree with a previous Danish study in which the use of antipsychotics was associated with a decreased risk for rectum, colon, and prostate cancer.\(^{16}\) Our study provides important population-based evidence and supports the Danish study results.

We investigated FGAs and SGAs to encompass most antipsychotics. After adjusted analysis, we found both FGAs and SGAs were associated with lower gastric cancer risk, and a trend of a dose-dependent relationship was also noted (Table 3). Our observations in this study revealed clear evidence of the advantages of antipsychotic use, and echo the results of previous experimental studies.\(^{8,9}\) Thus, safety concerns with current clinical antipsychotic use and the potential for novel treatment strategies for gastric cancer are highlighted in this study.

Considering the urgency in developing new, safe agents for gastric cancer treatment, we also analyzed individual antipsychotics to evaluate their effects on gastric cancer risk (Table 3). As in previous studies,\(^{8,9}\) we found that thioridazine could reduce gastric cancer risk with cDDDs \( \geq 168 \) in population-based environments. Therefore, it is crucial to emphasize accurate dosage adjustment when applying thioridazine in gastric cancer treatment. Aripiprazole did not show a protective trend in this study. Considering limited case numbers of aripiprazole use in this study, additional examination
### TABLE 3 Association between individual antipsychotics and gastric cancer risk

| ATC code | Generic name (cDDD<sup>a</sup>) | Gastric cancer, n = 34470 (%) | Non-gastric cancer, n = 163430 (%) | Adjusted odds ratio<sup>b</sup> (95% CI) | P value |
|----------|---------------------------------|-------------------------------|------------------------------------|------------------------------------------|---------|
| FGAs<sup>c</sup> | 0-27 | 33970 (98.55) | 159865 (97.82) | 1.00 [reference] | |
| | 28-83 | 351 (1.02) | 1917 (1.17) | 0.82 (0.73-0.93) | 0.0012 |
| | 84-167 | 72 (0.21) | 527 (0.32) | 0.66 (0.51-0.84) | 0.0009 |
| | ≥168 | 77 (0.22) | 1121 (0.69) | 0.39 (0.31-0.50) | <0.0001 |
| SGAs<sup>c</sup> | 0-27 | 34379 (99.74) | 162260 (99.28) | 1.00 [reference] | |
| | 28-83 | 53 (0.15) | 388 (0.24) | 0.64 (0.48-0.87) | 0.0034 |
| | 84-167 | 19 (0.06) | 242 (0.15) | 0.39 (0.24-0.63) | 0.0001 |
| | ≥168 | 19 (0.06) | 540 (0.33) | 0.21 (0.13-0.33) | <0.0001 |
| N05AC02 Thioridazine | 0-27 | 34425 (99.87) | 162976 (99.72) | 1.00 [reference] | |
| | 28-83 | 21 (0.06) | 140 (0.09) | 0.80 (0.50-1.27) | 0.35 |
| | 84-167 | 9 (0.03) | 72 (0.04) | 0.70 (0.35-1.41) | 0.32 |
| | ≥168 | 15 (0.04) | 242 (0.15) | 0.36 (0.21-0.62) | 0.0002 |
| N05AD01 Haloperidol | 0-27 | 34422 (99.86) | 162700 (99.55) | 1.00 [reference] | |
| | 28-83 | 25 (0.07) | 303 (0.19) | 0.44 (0.29-0.67) | 0.0001 |
| | 84-167 | 12 (0.03) | 127 (0.08) | 0.52 (0.29-0.95) | 0.035 |
| | ≥168 | 11 (0.03) | 300 (0.18) | 0.25 (0.14-0.46) | <0.0001 |
| N05AL01 Sulpiride | 0-27 | 34142 (99.05) | 161140 (98.60) | 1.00 [reference] | |
| | 28-83 | 246 (0.71) | 1405 (0.86) | 0.81 (0.70-0.93) | 0.0024 |
| | 84-167 | 46 (0.13) | 365 (0.22) | 0.62 (0.46-0.85) | 0.0027 |
| | ≥168 | 36 (0.10) | 520 (0.32) | 0.42 (0.30-0.60) | <0.0001 |
| N05AH02 Clozapine | 0-27 | 34466 (99.99) | 163338 (99.94) | 1.00 [reference] | |
| | ≥28 | 4 (0.01) | 92 (0.06) | 0.35 (0.13-0.97) | 0.043 |
| N05AH03 Olanzapine | 0-27 | 34466 (99.99) | 163218 (99.87) | 1.00 [reference] | |
| | ≥28 | 4 (0.01) | 212 (0.13) | 0.13 (0.05-0.35) | <0.0001 |

(Continues)
| ATC code | Generic name (cDDD<sup>a</sup>) | Gastric cancer, n = 34470 (%) | Non-gastric cancer, n = 163430 (%) | Adjusted odds ratio<sup>b</sup> (95% CI) | P value |
|----------|-------------------------------|-------------------------------|------------------------------------|----------------------------------------|---------|
| N05AH04  | Quetiapine                     |                               |                                    |                                        |         |
| 0-27     | 34432 (99.89)                 | 162987 (99.73)                | 1.00 [reference]                   |                                        |         |
| 28-83    | 22 (0.06)                     | 212 (0.13)                    | 0.46 (0.30-0.72)                   | 0.0007                                 |         |
| 84-167   | 12 (0.03)                     | 104 (0.06)                    | 0.52 (0.28-0.95)                   | 0.033                                  |         |
| ≥168     | 4 (0.01)                      | 127 (0.08)                    | 0.18 (0.07-0.49)                   | 0.0008                                 |         |
| N05AL05  | Amisulpride                    |                               |                                    |                                        |         |
| 0-27     | 34466 (99.99)                 | 163348 (99.95)                | 1.00 [reference]                   |                                        |         |
| ≥28      | 4 (0.01)                      | 82 (0.05)                     | 0.35 (0.13-0.97)                   | 0.043                                  |         |
| N05AX08  | Risperidone                   |                               |                                    |                                        |         |
| 0-27     | 34425 (99.87)                 | 162785 (99.61)                | 1.00 [reference]                   |                                        |         |
| 28-83    | 29 (0.08)                     | 236 (0.14)                    | 0.65 (0.44-0.97)                   | 0.033                                  |         |
| 84-167   | 7 (0.02)                      | 123 (0.08)                    | 0.34 (0.16-0.74)                   | 0.0063                                 |         |
| ≥168     | 9 (0.03)                      | 286 (0.17)                    | 0.21 (0.10-0.40)                   | <0.0001                                |         |
| N05AX12  | Aripiprazole                  |                               |                                    |                                        |         |
| 0-27     | 34468 (99.99)                 | 163389 (99.97)                | 1.00 [reference]                   |                                        |         |
| ≥28      | 2 (0.01)                      | 41 (0.03)                     | 0.34 (0.08-1.41)                   | 0.14                                   |         |

Abbreviations: ATC, Anatomical Therapeutic Chemical; cDDD, cumulative defined daily dose; CI, confidence interval; FGAs, first-generation antipsychotics; NSAIDs, nonsteroidal anti-inflammatory drugs; SGAs, second-generation antipsychotics.

<sup>a</sup>Drug dose usage is the cumulative defined daily dose excluding the year before the index date.

<sup>b</sup>Adjusted for sex, age, income, urbanization, hypertension, diabetes, hypercholesterolemia, chronic kidney disease, depressive disorder, peptic ulcer, alcohol-related liver disease, psychotic disorder, anxiety disorder, aspirin, NSAIDs, and triple therapy.

<sup>c</sup>FGAs and SGAs are listed in the appendix.
of aripiprazole’s effects is needed. Other antipsychotic compounds showed dose-dependent trends in reducing the risk of gastric cancer risk, but they had different protective effects. Some previous studies provided the possible explanation: specific chemical structures of antipsychotics such as the length of the alkyl bridge, substitutions on the phenothiazine ring, and the cyclic tertiary amine were related to affinity and potency toward dopamine receptors, and might determine the antitumor effect.24-27 In the future, studies should be performed to confirm the relationship between the structure characteristics of each antipsychotic and the ability against gastric cancer cells.

Sensitivity analysis was also conducted to examine the influences of a peptic ulcer history. A history of peptic ulcers did not modulate the protective effects of antipsychotic use on gastric cancer risk. Further investigation of the underlying mechanisms is warranted.

5 | CONCLUSION

This is the first population-based study to survey the association between common antipsychotics and gastric cancer risk. Our study highlights that antipsychotic use is inversely associated with gastric cancer risk.

6 | STUDY LIMITATIONS

There were some methodological limitations in this study. The cumulative doses of antipsychotics might be overestimated from pharmacy records because exact drug utilization could not be confirmed. Further studies of the optimal dosages of antipsychotics for gastric cancer treatment are needed. In addition, confounding factors such as family history of gastric cancer, body mass index, diet, smoking, and detailed alcohol intake were not included in the analysis. Although we controlled for alcohol-related disease and COPD, the effects of confounding factors were not totally avoided.

Our study has several strengths. The study design reduced possible selection and recall bias. In addition, we included information on the temporal relationship between antipsychotic exposure and gastric cancer. Further sensitivity analysis also minimized a major possible confounding factor, peptic ulcer disease, leading to more convincing data.

7 | CLINICAL IMPLICATIONS

Our study demonstrated that antipsychotic use was independently inversely associated with gastric cancer risk after controlling for potential confounding factors. Dose-dependent

| TABLE 4 | Antipsychotic use and gastric cancer risk in subgroups with and without peptic ulcer |

| Antipsychotics, cDDDb | Peptic ulcer (+) | Peptic ulcer (−) |
|-----------------------|-----------------|-----------------|
|                       | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| Antipsychotics, cDDDb |                 |           |                 |           |
| 0-27                  | 1.00 [reference] | 1.00 [reference] |           |           |
| 28-83                 | 0.70 (0.57-0.84) | 0.0002 | 0.96 (0.79-1.16) | 0.65 |
| 84-167                | 0.66 (0.45-0.99) | 0.043 | 0.54 (0.37-0.80) | 0.0023 |
| ≥168                  | 0.44 (0.30-0.66) | <0.0001 | 0.30 (0.21-0.44) | <0.0001 |
| FGAs, cDDDb           |                 |           |                 |           |
| 0-27                  | 1.00 [reference] | 1.00 [reference] |           |           |
| 28-83                 | 0.68 (0.56-0.83) | 0.0001 | 0.95 (0.78-1.16) | 0.60 |
| 84-167                | 0.66 (0.43-1.02) | 0.060 | 0.79 (0.54-1.16) | 0.23 |
| ≥168                  | 0.54 (0.36-0.80) | 0.002 | 0.32 (0.22-0.47) | <0.0001 |
| SGAs, cDDDb           |                 |           |                 |           |
| 0-27                  | 1.00 [reference] | 1.00 [reference] |           |           |
| 28-83                 | 0.72 (0.45-1.16) | 0.17 | 0.67 (0.44-1.02) | 0.059 |
| 84-167                | 0.48 (0.22-1.05) | 0.067 | 0.36 (0.18-0.73) | 0.0042 |
| ≥168                  | 0.21 (0.10-0.45) | <0.0001 | 0.19 (0.10-0.38) | <0.0001 |

Abbreviations: cDDD, cumulative defined daily dose; CI, confidence interval; FGAs, first-generation antipsychotics; NSAIDs, nonsteroidal anti-inflammatory drugs; SGAs, second-generation antipsychotics.
aAdjusted for sex, age, income, urbanization, hypertension, diabetes, hypercholesterolemia, chronic kidney disease, depressive disorder, alcohol-related liver disease, psychotic disorder, anxiety disorder, aspirin, NSAIDs, and triple therapy.
bDrug dose usage is the cDDD excluding the year before the index date.
protective trends against gastric cancer were also considered in several individual antipsychotics. The totality of the evidence is important not only for safety concerns with current clinical use, but also in the potential for novel treatment strategies for gastric cancer.

**ORCID**

Yi-Hsuan Hsieh  https://orcid.org/0000-0003-3023-0731

Vincent Chin-Hung Chen  https://orcid.org/0000-0002-1971-4922

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69-90.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. *Int J Cancer*. 1993;55(6):891-903.
3. Sisic L, Blank S, Nienhüser H, et al. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophageogastric adenocarcinoma. *Surg Oncol*. 2017; EPub ahead of print. https://doi.org/10.1016/j.suronc.2017.06.001.
4. Sisic L, Strizwitzki MI, Blank S, et al. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. *Gastric Cancer*. 2018;21(3):552–568.
5. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. *Clin Cancer Res*. 2004;10(13):4349-4356.
6. Ganguly S, Basu B, Shome S, et al. Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Kruppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation. *Am J Pathol*. 2010;177(6):2701-2707.
7. Huang H, Wu K, Ma J, Du Y, Cao C, Nie Y. Dopamine D2 receptor suppresses gastric cancer cell invasion and migration via inhibition of EGFR/AKT/MMP-13 pathway. *Int Immunopharmacol*. 2016;39:113-120.
8. Mu J, Xu H, Yang YU, et al. Thiioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. *Oncol Rep*. 2014;31(5):2107-2114.
9. Mu J, Huang W, Tan Z, et al. Dopamine receptor D2 is correlated with gastric cancer prognosis. *Oncol Lett*. 2017;13(3):1223-1227.
10. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol*. 2012;13(6):607-615.
11. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. *Gastroenterol Clin North Am*. 2013;42(2):219-240.
12. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. *Int Journal Cancer*. 2015;136(2):487-490.
13. Morishita S, Nishimori I, Minakuchi T, et al. Cloning, polymorphism, and inhibition of beta-carboxy anhydrase of Helicobacter pylori. *J Gastroenterol*. 2008;43(11):849-857.
14. Asmari AA, Arshaduddin M, Elfaki I, Kadasah S, Robayan AA, Asmary SA. Aripiprazole an atypical antipsychotic protects against ethanol induced gastric ulcers in rats. *Int J Clin Exp Med*. 2014;7(8):2031-2044.
15. Saxena B, Krishnamurthy S, Singh S. Gastroprotective potential of risperidone, an atypical antipsychotic, against stress and pyloric ligation induced gastric lesions. *Chem Biol Interact*. 2011;190(2–3):155-164.
16. Dalton SO, Johansen C, Poulsen AH, et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. *Br J Cancer*. 2006;95(7):934-939.
17. WHO. Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2019. https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf/. Accessed 2 Jun. 2019.
18. Chou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. *Schizophr Res*. 2011;129(2–3):97-103.
19. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. *Cancer Causes Control*. 2008;19(7):689-701.
20. Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. *Ann Oncol*. 2012;23(1):28-36.
21. Venerito M, Vasapoli R, Rokkas T, Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. *Helicobacter*. 2018;23(Suppl 1):e12518.
22. Shichijo S, Hirata Y. Characteristics and predictors of gastric cancer after Helicobacter pylori eradication. *World J Gastroenterol*. 2018;24(20):2163-2172.
23. Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. *Gastroenterology*. 2016;150(5):1113-1124.e5.
24. Roney M, Park SK. Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells. *Arch Pharm Res*. 2018;41(4):384-408.
25. Tsakovska I, Pajeva I. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. *Curr Drug Targets*. 2006;7(9):1123-1134.
26. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. *Cancer Chemother Pharmacol*. 1992;30(3):165-173.
27. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. *Mol Pharmacol*. 1989;35(1):105-115.

**How to cite this article:** Hsieh Y-H, Chan H-L, Lin C-F, et al. Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study. *Cancer Med*. 2019;8:4484–4496. https://doi.org/10.1002/cam4.2329
## APPENDIX 1

### TABLE A1  ATC code and drug name

| First generation antipsychotics |   |
|----------------------------------|---|
| **ATC code** | **Drug name** |
| N05AA01 | chlorpromazine |
| N05AA02 | levomepromazine |
| N05AB02 | fluphenazine |
| N05AB03 | perphenazine |
| N05AB04 | prochlorperazine |
| N05AB06 | trifluoperazine |
| N05AC02 | thioridazine |
| N05AD01 | haloperidol |
| N05AF01 | flupentixol |
| N05AF02 | clopenthixol |
| N05AF03 | chlorprothixene |
| N05AF05 | zuclopenthixol |
| N05AG02 | pimozide |
| N05AH01 | loxapine |
| N05AL01 | sulpiride |

| Second generation antipsychotics |   |
|----------------------------------|---|
| **ATC code** | **Drug name** |
| N05AE04 | ziprasidone |
| N05AH02 | clozapine |
| N05AH03 | olanzapine |
| N05AH04 | quetiapine |
| N05AL05 | amisulpride |
| N05AX08 | risperidone |
| N05AX11 | zotepine |
| N05AX12 | aripiprazole |
| N05AX13 | paliperidone |
## APPENDIX 2

### TABLE A2  Association between duration of individual antipsychotics and gastric cancer risk

| ATC code | Generic name (day) | Gastric cancer, n = 34470 (%) | Non-gastric cancer, n = 163430 (%) | Adjusted odds ratio\(^b\) (95% CI) | P value |
|----------|--------------------|-------------------------------|-----------------------------------|-----------------------------------|---------|
| **Antipsychotics** |                     |                               |                                   |                                   |         |
| 0-27     |                    | 31830 (92.34)                 | 149808 (91.66)                    | 1.00 [reference]                  |         |
| 28-83    |                    | 1580 (4.54)                   | 7345 (4.49)                       | 0.95 (0.90-1.01)                  | 0.073   |
| 84-167   |                    | 543 (1.58)                    | 2473 (1.51)                       | 0.97 (0.88-1.07)                  | 0.38    |
| ≥168     |                    | 517 (1.50)                    | 3804 (2.33)                       | 0.65 (0.59-0.72)                  | <0.0001 |
| **FGAs\(^c\)** |                    | 31898 (92.54)                 | 150256 (91.94)                    | 1.00 [reference]                  |         |
| 0-27     |                    | 1565 (4.54)                   | 7316 (4.48)                       | 0.95 (0.90-1.01)                  | 0.073   |
| 84-167   |                    | 528 (1.53)                    | 2451 (1.50)                       | 0.96 (0.87-1.06)                  | 0.38    |
| ≥168     |                    | 479 (1.39)                    | 3407 (2.08)                       | 0.68 (0.61-0.75)                  | <0.0001 |
| **SGAs\(^c\)** |                    | 34253 (99.37)                 | 161519 (98.83)                    | 1.00 [reference]                  |         |
| 0-27     |                    | 82 (0.24)                     | 476 (0.29)                        | 0.75 (0.59-0.96)                  | 0.02    |
| 84-167   |                    | 41 (0.12)                     | 290 (0.18)                        | 0.66 (0.48-0.93)                  | 0.02    |
| ≥168     |                    | 94 (0.27)                     | 1145 (0.27)                       | 0.42 (0.33-0.52)                  | <0.0001 |
| **N05AC02** | Thioridazine | 34438 (99.91)                 | 163040 (99.76)                    | 1.00 [reference]                  |         |
| 0-27     |                    | 18 (0.05)                     | 155 (0.09)                        | 0.62 (0.38-1.01)                  | 0.054   |
| 84-167   |                    | 4 (0.01)                      | 71 (0.04)                         | 0.31 (0.11-0.86)                  | 0.025   |
| ≥168     |                    | 10 (0.03)                     | 164 (0.10)                        | 0.37 (0.19-0.70)                  | 0.0022  |
| **N05AD01** | Haloperidol | 34354 (99.66)                 | 162224 (99.26)                    | 1.00 [reference]                  |         |
| 0-27     |                    | 58 (0.17)                     | 484 (0.30)                        | 0.59 (0.44-0.78)                  | 0.0002  |
| 84-167   |                    | 21 (0.06)                     | 214 (0.13)                        | 0.52 (0.33-0.82)                  | 0.0046  |
| ≥168     |                    | 37 (0.11)                     | 508 (0.31)                        | 0.43 (0.30-0.60)                  | <0.0001 |
| **N05AL01** | Sulpiride | 32858 (95.32)                 | 155206 (94.97)                    | 1.00 [reference]                  |         |
| 0-27     |                    | 960 (2.79)                    | 4430 (2.71)                       | 0.98 (0.91-1.05)                  | 0.50    |
| 84-167   |                    | 338 (0.98)                    | 1660 (1.02)                       | 0.93 (0.82-1.05)                  | 0.23    |
| ≥168     |                    | 314 (0.91)                    | 2134 (1.31)                       | 0.71 (0.63-0.80)                  | <0.0001 |

(Continues)
### TABLE A2 (Continued)

| ATC code | Generic name (day) | Gastric cancer, n = 34470 (%) | Non-gastric cancer, n = 163430 (%) | Adjusted odds ratio<sup>b</sup> (95% CI) | P value |
|----------|--------------------|------------------------------|-----------------------------------|----------------------------------------|---------|
| N05AH02  | Clozapine          |                              |                                   |                                        |         |
| 0-27     | 34461 (99.97)      | 163291 (99.91)               | 1.00 [reference]                  |                                       |         |
| ≥28      | 9 (0.03)           | 139 (0.09)                   | 0.46 (0.23-0.90)                  | 0.024                                  |         |
| N05AH03  | Olanzapine         |                              |                                   |                                        |         |
| 0-27     | 34463 (99.98)      | 163171 (99.84)               | 1.00 [reference]                  |                                       |         |
| ≥28      | 7 (0.02)           | 259 (0.16)                   | 0.18 (0.08-0.37)                  | <0.0001                                |         |
| N05AH04  | Quetiapine         |                              |                                   |                                        |         |
| 0-27     | 34293 (99.49)      | 162481 (99.42)               | 1.00 [reference]                  |                                       |         |
| 28-83    | 25 (0.07)          | 269 (0.16)                   | 0.46 (0.30-0.72)                  | <0.0001                                |         |
| 84-167   | 10 (0.03)          | 151 (0.09)                   | 0.52 (0.28-0.95)                  | 0.0004                                 |         |
| ≥168     | 142 (0.41)         | 529 (0.32)                   | 0.18 (0.07-0.49)                  | 0.023                                  |         |
| N05AL05  | Amisulpride        |                              |                                   |                                        |         |
| 0-27     | 34462 (99.98)      | 163321 (99.93)               | 1.00 [reference]                  |                                       |         |
| ≥28      | 8 (0.02)           | 109 (0.07)                   | 0.49 (0.24-1.02)                  | 0.057                                  |         |
| N05AX08  | Risperidone        |                              |                                   |                                        |         |
| 0-27     | 34381 (99.74)      | 162392 (99.36)               | 1.00 [reference]                  |                                       |         |
| 28-83    | 36 (0.10)          | 332 (0.20)                   | 0.52 (0.36-0.74)                  | 0.0003                                 |         |
| 84-167   | 17 (0.05)          | 186 (0.11)                   | 0.46 (0.28-0.76)                  | 0.0024                                 |         |
| ≥168     | 36 (0.10)          | 520 (0.32)                   | 0.41 (0.29-0.57)                  | <0.0001                                |         |
| N05AX12  | Aripiprazole       |                              |                                   |                                        |         |
| 0-27     | 34468 (99.99)      | 163373 (99.97)               | 1.00 [reference]                  |                                       |         |
| ≥28      | 2 (0.01)           | 57 (0.03)                    | 0.23 (0.06-0.96)                  | 0.044                                  |         |

Abbreviations: ATC, Anatomical Therapeutic Chemical; CI, confidence interval; FGAs, first-generation antipsychotics; NSAIDs, nonsteroidal anti-inflammatory drugs; SGAs, second-generation antipsychotics.

<sup>a</sup>Drug dose usage is the cumulative defined daily days excluding the year before the index date.

<sup>b</sup>Adjusted for sex, age, income, urbanization, hypertension, diabetes, hypercholesterolemia, chronic kidney disease, depressive disorder, peptic ulcer, alcohol-related liver disease, psychotic disorder, anxiety disorder, aspirin, NSAIDs, and triple therapy.

<sup>c</sup>FGAs and SGAs are listed in the appendix.